کد مقاله کد نشریه سال انتشار مقاله انگلیسی نسخه تمام متن
2569159 1128513 2012 8 صفحه PDF دانلود رایگان
عنوان انگلیسی مقاله ISI
2-(3-Methoxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (HKL-1) induces G2/M arrest and mitotic catastrophe in human leukemia HL-60 cells
موضوعات مرتبط
علوم زیستی و بیوفناوری علوم محیط زیست بهداشت، سم شناسی و جهش زایی
پیش نمایش صفحه اول مقاله
2-(3-Methoxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (HKL-1) induces G2/M arrest and mitotic catastrophe in human leukemia HL-60 cells
چکیده انگلیسی

2-(3-Methoxyphenyl)-5-methyl-1,8-naphthyridin-4(1H)-one (HKL-1), a 2-phenyl-1,8-naphthyridin-4-one (2-PN) derivative, was synthesized and evaluated as an effective antimitotic agent in our laboratory. However, the molecular mechanisms are uncertain. In this study, HKL-1 was demonstrated to induce multipolar spindles, sustain mitotic arrest and generate multinucleated cells, all of which indicate mitotic catastrophe, in human leukemia HL-60 cells. Western blotting showed that HKL-1 induces mitotic catastrophe in HL-60 cells through regulating mitotic phase-specific kinases (down-regulating CDK1, cyclin B1, CENP-E, and aurora B) and regulating the expression of Bcl-2 family proteins (down-regulating Bcl-2 and up-regulating Bax and Bak), followed by caspase-9/-3 cleavage. These findings suggest that HKL-1 appears to exert its cytotoxicity toward HL-60 cells in culture by inducing mitotic catastrophe.

Figure optionsDownload high-quality image (91 K)Download as PowerPoint slideHighlights
► HKL-1 is a potential antimitotic agent against HL-60 cells.
► HKL-1 induces spindle disruption and sustained resulted in mitotic catastrophe.
► CENP-E and aurora B protein expressions significantly reduced.
► Bcl-2 family protein expressions altered and caspase-9/-3 activation.
► HKL-1 is an attractive candidate for possible use as a novel antimitotic agent.

ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Toxicology and Applied Pharmacology - Volume 259, Issue 2, 1 March 2012, Pages 219–226
نویسندگان
, , , , , , , , ,